Janet L. Markman

2.3k total citations · 1 hit paper
21 papers, 1.5k citations indexed

About

Janet L. Markman is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Janet L. Markman has authored 21 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 7 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Janet L. Markman's work include Immunotherapy and Immune Responses (7 papers), Inflammasome and immune disorders (4 papers) and RNA Interference and Gene Delivery (3 papers). Janet L. Markman is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), Inflammasome and immune disorders (4 papers) and RNA Interference and Gene Delivery (3 papers). Janet L. Markman collaborates with scholars based in United States, Germany and Spain. Janet L. Markman's co-authors include Julia Y. Ljubimova, Arthur Rekechenetskiy, Stephen L. Shiao, Moshe Arditi, Shuang Chen, Keith L. Black, Bindu Konda, Eggehard Holler, Caroline A. Jefferies and Hui Ding and has published in prestigious journals such as Nature, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Janet L. Markman

20 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nanomedicine therapeutic approaches to overcome cancer drug resistance

2013 600 citations Janet L. Markman, Arthur Rekechenetskiy et al. Advanced Drug Delivery Reviews profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Janet L. Markman United States	15	581	429	382	372	351	21	1.5k
Bindu Konda United States	22	678 1.2×	322 0.8×	398 1.0×	289 0.8×	217 0.6×	27	1.6k
Meng Jia China	19	482 0.8×	220 0.5×	262 0.7×	427 1.1×	223 0.6×	36	1.4k
Ran Tian China	24	1.0k 1.7×	384 0.9×	320 0.8×	460 1.2×	223 0.6×	40	1.9k
Meng Zhou China	20	890 1.5×	450 1.0×	261 0.7×	349 0.9×	415 1.2×	46	1.9k
Alan Chan Netherlands	27	743 1.3×	292 0.7×	245 0.6×	725 1.9×	293 0.8×	73	2.1k
Yojiro Maehata Japan	16	748 1.3×	339 0.8×	371 1.0×	454 1.2×	247 0.7×	32	1.9k
Qin Fan China	24	927 1.6×	360 0.8×	382 1.0×	1.1k 2.9×	724 2.1×	47	2.3k
Tingting Lin China	12	467 0.8×	409 1.0×	206 0.5×	373 1.0×	151 0.4×	47	1.1k
Fang Xie China	21	489 0.8×	375 0.9×	451 1.2×	308 0.8×	611 1.7×	49	1.6k
Simmyung Yook South Korea	27	517 0.9×	599 1.4×	272 0.7×	749 2.0×	286 0.8×	78	1.9k

Countries citing papers authored by Janet L. Markman

Since Specialization

Citations

This map shows the geographic impact of Janet L. Markman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet L. Markman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet L. Markman more than expected).

Fields of papers citing papers by Janet L. Markman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet L. Markman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet L. Markman. The network helps show where Janet L. Markman may publish in the future.

Co-authorship network of co-authors of Janet L. Markman

This figure shows the co-authorship network connecting the top 25 collaborators of Janet L. Markman. A scholar is included among the top collaborators of Janet L. Markman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet L. Markman. Janet L. Markman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grabbe, Stephan, Michele Guida, Janet L. Markman, et al.. (2025). 1605MO Primary results from a randomized phase II trial of BNT111 in combination with cemiplimab with calibrator monotherapy arms in anti-PD-(L)1 relapsed/refractory melanoma. Annals of Oncology. 36. S885–S886.

Baz, David Vicente, Jürgen Wolf, Öztürk Ateş, et al.. (2024). Abstract CT051: Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen mRNA vaccine BNT116 + docetaxel in patients with advanced non-small cell lung cancer. Cancer Research. 84(7_Supplement). CT051–CT051. 6 indexed citations

Chu, Lulu, Pere Barba, Matteo Doglio, et al.. (2023). Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Frontiers in Immunology. 14. 1303935–1303935. 75 indexed citations

Göker, Erdem, István Láng, Patrick T. Bruck, et al.. (2023). 597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer. SHILAP Revista de lepidopterología. A679–A679. 7 indexed citations

Koyama, Takafumi, Toshio Shimizu, Toshihiko Doi, et al.. (2022). 737 Interim results of a first-in-human phase 1 dose-escalation trial of TAK-102, a glypican-3 targeted armored chimeric antigen receptor T-cell immunotherapy in patients with advanced solid tumors. Regular and Young Investigator Award Abstracts. A770–A770. 1 indexed citations

Chen, Shuang, Janet L. Markman, Kenichi Shimada, et al.. (2020). Sex-Specific Effects of the Nlrp3 Inflammasome on Atherogenesis in LDL Receptor-Deficient Mice. JACC Basic to Translational Science. 5(6). 582–598. 46 indexed citations

O’Rourke, Jacqueline G., Alberto Yáñez, Janet L. Markman, et al.. (2020). C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature. 585(7823). 96–101. 203 indexed citations

Tumurkhuu, Gantsetseg, Shuang Chen, Erica N. Montano, et al.. (2020). Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-Induced Lupus Model. Frontiers in Immunology. 11. 554725–554725. 39 indexed citations

Markman, Janet L., Rebecca A. Porritt, Daiko Wakita, et al.. (2020). Loss of testosterone impairs anti-tumor neutrophil function. Nature Communications. 11(1). 44 indexed citations

10.

Porritt, Rebecca A., Janet L. Markman, Daisuke Maruyama, et al.. (2020). Interleukin-1 Beta–Mediated Sex Differences in Kawasaki Disease Vasculitis Development and Response to Treatment. Arteriosclerosis Thrombosis and Vascular Biology. 40(3). 802–818. 43 indexed citations

11.

Shimada, Kenichi, Rebecca A. Porritt, Janet L. Markman, et al.. (2018). T-Cell-Intrinsic Receptor Interacting Protein 2 Regulates Pathogenic T Helper 17 Cell Differentiation. Immunity. 49(5). 873–885.e7. 20 indexed citations

12.

Markman, Janet L. & Stephen L. Shiao. (2015). Impact of the immune system and immunotherapy in colorectal cancer.. PubMed. 6(2). 208–23. 156 indexed citations

13.

Patil, Rameshwar, Alexander V. Ljubimov, Pallavi R. Gangalum, et al.. (2015). MRI Virtual Biopsy and Treatment of Brain Metastatic Tumors with Targeted Nanobioconjugates: Nanoclinic in the Brain. ACS Nano. 9(5). 5594–5608. 73 indexed citations

14.

Ljubimova, Julia Y., Michael T. Kleinman, Satoshi Inoue, et al.. (2013). Gene expression changes in rat brain after short and long exposures to particulate matter in Los Angeles basin air: Comparison with human brain tumors. Experimental and Toxicologic Pathology. 65(7-8). 1063–1071. 22 indexed citations

15.

Markman, Janet L., et al.. (2013). Nanomedicine therapeutic approaches to overcome cancer drug resistance. Advanced Drug Delivery Reviews. 65(13-14). 1866–1879. 600 indexed citations breakdown →

16.

Ljubimova, Julia Y., José Portilla‐Arias, Rameshwar Patil, et al.. (2013). Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment. Journal of drug targeting. 21(10). 956–967. 44 indexed citations

17.

Ljubimova, Julia Y., Rameshwar Patil, Pallavi R. Gangalum, et al.. (2013). Abstract A50: Nanobiocojugates of differential imaging and treatment of brain metastatic tumors. Cancer Research. 73(3_Supplement). A50–A50. 1 indexed citations

18.

Ding, Hui, Gustavo Helguera, José A. Rodríguez, et al.. (2013). Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer. Journal of Controlled Release. 171(3). 322–329. 37 indexed citations

19.

Inoue, Satoshi, Rameshwar Patil, José Portilla‐Arias, et al.. (2012). Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer. PLoS ONE. 7(2). e31070–e31070. 45 indexed citations

20.

Markman, Janet L., et al.. (2012). Treg cells in pancreatic lymph nodes: the possible role in diabetogenesis and β cell regeneration in a T1D model. Cellular and Molecular Immunology. 9(6). 455–463. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact